Immuneering (IMRX) Current Leases (2020 - 2024)
Immuneering has reported Current Leases over the past 5 years, most recently at $324702.0 for Q3 2024.
- Quarterly results put Current Leases at $324702.0 for Q3 2024, up 7.65% from a year ago — trailing twelve months through Sep 2024 was $324702.0 (up 7.65% YoY), and the annual figure for FY2023 was $300107.0, down 20.76%.
- Current Leases for Q3 2024 was $324702.0 at Immuneering, up from $311459.0 in the prior quarter.
- Over the last five years, Current Leases for IMRX hit a ceiling of $378723.0 in Q4 2022 and a floor of $76322.0 in Q4 2020.
- Median Current Leases over the past 5 years was $300107.0 (2023), compared with a mean of $265688.5.
- Biggest five-year swings in Current Leases: surged 272.84% in 2022 and later dropped 20.76% in 2023.
- Immuneering's Current Leases stood at $76322.0 in 2020, then surged by 259.06% to $274039.0 in 2021, then soared by 38.2% to $378723.0 in 2022, then dropped by 20.76% to $300107.0 in 2023, then rose by 8.2% to $324702.0 in 2024.
- The last three reported values for Current Leases were $324702.0 (Q3 2024), $311459.0 (Q2 2024), and $298543.0 (Q1 2024) per Business Quant data.